Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Commercial and Pipeline Insight - Infertility - Optimizing a market bounded by social opinion and physician preference (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 10 Oct 2007
- Report Title: Commercial and Pipeline Insight - Infertility - Optimizing a market bounded by social opinion and physician preference
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 189
Introduction
The market for infertility drugs is a complex and dynamic arena shaped by numerous factors such as changing social attitudes, national legislation, and prescriber preferences. Brand strength and diverse portfolios have allowed Organon, Merck Serono and Ferring to secure a firm foothold in the market, worth over $1 billion in 2006, and represent tough competition.
Scope
Analysis of patient potential, unmet needs, market dynamics, and clinical trial design in infertility, supported by opinion leader comment Assessment of pipeline drugs and future treatment trends and their impact on prescribing patterns and behavior Patient based and sales based market forecasts to 2016, the latter providing a breakdown by region, drug class, marketed brands and pipeline drugs Coverage of emerging infertility markets which, in light of reproductive tourism, may offer revenue growth potential
Highlights
Key differentiators will permit Organon's Org-36286 (corifollitropin alpha) and Merck Serono's Pergoveris (r-FSH and r-LH), to cannibalize some share from their proprietors' franchise leading therapies. However, these agents do not appear to satisfy unmet need and this will prevent sales from rivaling Puregon and Menopur (hMG). The lack of education of non-specialist physicians limits the number of women receiving treatment. It should be a primary goal of the market to make these doctors more knowledgeable and to implement incentives to encourage patient referral. New opportunities exist in the development of products to support embryological techniques; cryopreservation, microarrays and in vitro maturation. These procedures will expand the treatable patient population as all women with the intention of preserving and protecting embryos will be eligible for treatment, not just those that are infertile.
Reasons to Purchase
Quantify the future size of the infertility market and the number of women eligible for infertility treatment to 2016 in the US, 5EU, and Japan Understand unmet needs and opportunities in the infertility market based on key opinion leader comments Benchmark key late-stage infertility compounds against current market leading brands
The market for infertility drugs is a complex and dynamic arena shaped by numerous factors such as changing social attitudes, national legislation, and prescriber preferences. Brand strength and diverse portfolios have allowed Organon, Merck Serono and Ferring to secure a firm foothold in the market, worth over $1 billion in 2006, and represent tough competition.
Scope
Analysis of patient potential, unmet needs, market dynamics, and clinical trial design in infertility, supported by opinion leader comment Assessment of pipeline drugs and future treatment trends and their impact on prescribing patterns and behavior Patient based and sales based market forecasts to 2016, the latter providing a breakdown by region, drug class, marketed brands and pipeline drugs Coverage of emerging infertility markets which, in light of reproductive tourism, may offer revenue growth potential
Highlights
Key differentiators will permit Organon's Org-36286 (corifollitropin alpha) and Merck Serono's Pergoveris (r-FSH and r-LH), to cannibalize some share from their proprietors' franchise leading therapies. However, these agents do not appear to satisfy unmet need and this will prevent sales from rivaling Puregon and Menopur (hMG). The lack of education of non-specialist physicians limits the number of women receiving treatment. It should be a primary goal of the market to make these doctors more knowledgeable and to implement incentives to encourage patient referral. New opportunities exist in the development of products to support embryological techniques; cryopreservation, microarrays and in vitro maturation. These procedures will expand the treatable patient population as all women with the intention of preserving and protecting embryos will be eligible for treatment, not just those that are infertile.
Reasons to Purchase
Quantify the future size of the infertility market and the number of women eligible for infertility treatment to 2016 in the US, 5EU, and Japan Understand unmet needs and opportunities in the infertility market based on key opinion leader comments Benchmark key late-stage infertility compounds against current market leading brands
Browse over 450,000 market research reports, company profile reports and company financials. Search by industry sector, or simply search market research reports or company profiles by keyword. Companiesandmarkets.com contains one of the world's largest collections of market research reports and company profiles from leading global market research report publishers and analysts. Global brands rely on companiesandmarkets.com for their strategic market research needs.
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card, Credit Card, or by Invoice.
Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
